Sissel Rodahl
Corporate Officer/Principal bij GENSIGHT BIOLOGICS S.A.
Profiel
Sissel Rodahl is currently the Senior Vice President-Commercial Operations at Gensight Biologics SA since 2022.
Prior to this, she worked as Vice President at Novartis Gene Therapies, Inc. from 2018 to 2022.
She completed her graduate degree from the University of Oslo and her undergraduate degree from Engineering College.
Actieve functies van Sissel Rodahl
| Bedrijven | Functie | Begin |
|---|---|---|
| GENSIGHT BIOLOGICS S.A. | Corporate Officer/Principal | 31-01-2022 |
Eerdere bekende functies van Sissel Rodahl
| Bedrijven | Functie | Einde |
|---|---|---|
| AVEXIS INC | Corporate Officer/Principal | 01-02-2022 |
Opleiding van Sissel Rodahl
| University of Oslo | Graduate Degree |
| Engineering College | Undergraduate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 1 |
|---|---|
| GENSIGHT BIOLOGICS S.A. | Health Technology |
| Bedrijven in privébezit | 1 |
|---|---|
Novartis Gene Therapies, Inc.
 Novartis Gene Therapies, Inc. BiotechnologyHealth Technology Novartis Gene Therapies, Inc. developed gene therapies for patients and families devastated by rare and life-threatening neurological genetic diseases. The firm’s robust AAV-based pipeline is used to provide advance treatments for Rett syndrome and Friedreich’s ataxia. The company was founded by John D. Harkey, Jr., David G. Genecov and John A. Carbona on March 8, 2010 and was headquartered in Bannockburn, IL. | Health Technology |
